DRUG SUPPLY AGREEMENTDrug Supply Agreement • February 16th, 2010 • Pharmacyclics Inc • Pharmaceutical preparations
Contract Type FiledFebruary 16th, 2010 Company IndustryPharmacyclics and Servier have entered into a Collaboration Agreement, effective April 9, 2009 to co-develop the HDAC Inhibitor identified as [**]or PCI-24781 (Pharmacyclics). Pursuant to Section 4.3 of the Collaboration Agreement, Pharmacyclics has agreed to use “Reasonable Efforts” (as defined in the Collaboration Agreement) to manufacture or have manufactured quantities of [**]for clinical use by Servier. With this agreement (the “Agreement”), Pharmacyclics will facilitate the manufacture of a targeted amount of [**] cGMP quality [**]through its Third Party Manufacturing organizations. The terms of this Agreement shall not amend the Collaboration Agreement signed on April 9th, 2009, which specifies under Section 4.3 that a supply agreement shall be negotiated between the parties containing terms consistent with such Section 4.3 and such other terms as are reasonable and customary for arrangements of this type.
AGREEMENT AND RELEASEAgreement and Release • February 16th, 2010 • Pharmacyclics Inc • Pharmaceutical preparations
Contract Type FiledFebruary 16th, 2010 Company IndustryAgreement and Release (“Agreement”) executed this 28th day of October, 2009, by and between Glenn Rice (“Employee”) with an address at ____________________________________ and Pharmacyclics, Inc., its parents, subsidiaries and affiliates (the “Company”) with an address a 996 E. Arques Avenue, Sunnyvale, California 94085.